Original Article

Methylsulfonylmethane decreases inflammatory response to tumor necrosis factor-α in cardiac cells

Lindsey E Miller

Department of Nutrition and Exercise Physiology, Elson S. Floyd College of Medicine, Washington State University, USA

Received April 19, 2018; Accepted June 6, 2018; Epub June 15, 2018; Published June 25, 2018

Abstract: The development of various cardiovascular diseases (CVDs) are associated with chronic inflammation. Tumor necrosis factor α (TNF-α) is a pro-inflammatory cytokine that activates the nuclear factor-κB (NF-κB) signaling pathway, leading to increased inflammatory cytokine expression, such as interleukin-6 (IL-6). Interventions to reduce each of these factors have been demonstrated to reduce the development of CVD. Methylsulfonylmethane (MSM) is a naturally occurring compound that demonstrates anti-inflammatory effects in humans and various animal and cell culture models. The effects of MSM include decreased NF-κB activation, decreased expression of TNF-α, and IL-6. However, the effects of MSM within the heart have not yet been examined. Therefore, the purpose of this investigation was to determine whether MSM protects cardiac cells from inflammation that occurs in response to pro-inflammatory stimuli. A novel immortalized human ventricular cardiomyocyte cell line, designated Ac16, developed and characterized in the laboratory of Dr. Mercy Davidson, Columbia Invention Report No. 823, U.S. patent No. 7,223,599 were utilized. Cells were treated with TNF-α, alone or in combination with MSM. To confirm an appropriate dosage of MSM, the effect of various concentrations on cell viability, and IL-6 production were examined. The effect of MSM on transcript expression of pro-inflammatory markers and activation of NF-κB were examined with the established dose by real-time quantitative PCR and western blot, respectively. MSM treatment combined with TNF-α significantly decreased IL-6 production and transcript expression compared to TNF-α alone. These findings indicate that MSM may protect against inflammation in the heart, and thereby protect against inflammation-linked CVDs. Further study is warranted to determine the effect of MSM on cardiovascular health outcomes.

Keywords: Methylsulfonylmethane, MSM, cardiac, inflammation, TNF-α, IL-6, NF-κB

Introduction

Cardiovascular disease (CVD) remains the leading cause of death in the world [1]. Chronic inflammation and oxidative stress are associated with the development of various cardiovascular diseases including hypertension, heart failure, cardiac fibrosis, and diabetic cardiomyopathy [2-5].

The identification of mechanisms by which chronic inflammation and oxidative stress contribute to the development of CVDs is an active area of research for the discovery of future treatments and preventative interventions. Studies have identified pro-inflammatory signaling factors such as nuclear factor-κB (NF-κB), tumor necrosis factor α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) as important mediators in the development of CVDs [6-9]. Interventions to reduce NF-κB expression, inflammatory cytokines, and reactive oxygen species (ROS) have been demonstrated to reduce the development of CVDs, including heart failure and cardiac fibrosis [10, 11]. Therefore, novel strategies to decrease cardiac inflammation and ROS hold promise to inhibit the development of CVDs.

Methylsulfonylmethane (MSM) is a naturally occurring compound that demonstrates antioxidant and anti-inflammatory effects both in vivo and in vitro [12-14]. In macrophages, MSM inhibits mitochondrial ROS production, decreases protein expression of pro-IL-1β, TNF-α, and transcript expression of IL-6 [15]. Furthermore, Kim and colleagues demonstrated that MSM blocks NF-κB activation, thereby inhibiting NF-
Methylsulfonylmethane decreases inflammatory response to TNF-α in cardiac cells

κB mediated transcription of inflammatory genes [14]. Collectively, these findings support a beneficial role of MSM in disease states associated with chronic inflammation and oxidative stress. However, the effects of MSM within cardiac cells had not yet been examined. Therefore, the purpose of this investigation was to determine whether MSM protects cardiac cells from oxidative stress and inflammation induced by pro-inflammatory stimuli.

Materials and methods

Cell culture

A novel immortalized human ventricular cardiomyocyte cell line, designated Ac16, developed and characterized in the laboratory of Dr. Mercy Davidson [16], relating to Columbia Invention Report No. 823 and covered by U.S. patent No. 7,223,599 were utilized in this study. Ac16 cells were cultured in Gibco DMEM (ThermoFisher Scientific, Carlsbad, CA.), with 5.5% glucose and 12.5% fetal bovine serum and maintained at 37°C and 5% CO₂. Cells were split at 75% confluence. 24 hours prior to all treatments, medium was replaced with DMEM containing 5.5% glucose and 1% fetal bovine serum. Application of TNF-α (10 ng/ml) was utilized as a model of pro-inflammatory signaling.

Cell viability and proliferation assays

Ac16 Cells were plated in 96-well format and treated with various concentrations (0, 5, 10, 20 or 40 mg/ml) of MSM (OptiMSM®, Bergstrom Nutrition, Vancouver, WA.) for 24 hours, n=3. Assessment of cell viability and cytotoxicity was completed via the CellTiter96Aqueous assay (Promega, Madison, WI) and cell proliferation by the MTT assay (MilliporeSigma, St. Louis, MO), following manufacturer’s instructions.

Culture medium analysis

Ac16 cells were treated as Control or with TNF-α (10 ng/ml) alone and in combination with various concentrations of MSM (2.5, 5.0 or 10.0 mg/ml) for 24 hours, n=4. Culture medium was collected and stored at -80 for IL-6 analysis. IL-6 levels were assessed utilizing a commercially available kit following manufacturer’s instructions (ThermoScientific, Carlsbad, CA.).

Real time quantitative PCR

Ac16 cells were treated as Control, with MSM (10 mg/ml), with TNF-α (10 ng/ml), or MSM and TNF-α for 24 hours, n=4 per group. Cells were harvested with RNA Protect Cell Reagent (Qiagen, Valencia, CA.) and stored at -80 until analysis. Total RNA was extracted using the RNeasy Protect Cell Mini Kit (Qiagen, Valencia, CA.). cDNA was synthesized using the Verso cDNA synthesis kit (ThermoFisher Scientific, Carlsbad, CA.). Primers were purchased from Integrated DNA Technologies (IDT, Coralville, IA), sequences are provided in Table 1. Transcript expression of NF-κB1 & 2, inhibitor of κB (IκB), IL-6, interleukin-6, IL-1, interleukin-1, TBP, TATA binding Protein.

Cell fractionation and western blotting

Ac16 cells were treated as Control or with TNF-α (10 ng/ml) alone or in combination with MSM (10 mg/ml), n=3. Cells were harvested at 30 minutes post treatment. Briefly, cells were trypsinized and centrifuged for 5 minutes at 37°C. The cell pellet was washed and re-suspended in ice-cold PBS, transferred to a microcentrifuge tube and centrifuged 5 minutes

| Table 1. Primers for real time qPCR analysis |
|-----------------|-----------------|-----------------|
| NF-κB1 Forward  | CAGTTGGTGCCCTCAGTCAAA |
| Reverse         | GAGCAACGGGATGGAATTTT |
| NF-κB2 Forward  | GAAGATTGACGCGCTGTTA |
| Reverse         | TGCCTCACCAGAGGTAATA |
| IkB Forward     | TACCCAGGCTATCTCCTTAC |
| Reverse         | TGGCAGCATCTGGAAGTTT |
| IL-6 Forward    | ATTCTGCACAGCTTAAGGA |
| Reverse         | GAGGTGCCCCTACGTTAGTT |
| IL-1 Forward    | CAAAGGGCGCCAGGATAAA |
| Reverse         | CAGGGATTGAGTCACATTCAG |
| TBP Forward     | ATGTTGACGGAGTGTTG |
| Reverse         | CCCAGTACGCGACTGTTAT |

NF-κB, Nuclear factor-κB, IkB, inhibitor of κB, IL-6, interleukin-6, IL-1, interleukin-1, TBP, TATA binding Protein.
Methylsulfonylmethane decreases inflammatory response to TNF-α in cardiac cells

at 4°C. Fractionations were separated utilizing a Subcellular fractionation kit (ThermoFisher Scientific, Carlsbad, CA.), following the manufacturer’s instructions. For western blot of cellular fractions, both nuclear and cytoplasmic samples were thawed on ice. Total protein content was assessed by the DC protein assay (BioRad, Irvine, CA.). Samples were diluted in phosphate buffered saline to normalize the protein concentration, mixed 1:1 with laemmlki sample buffer containing 5% β-mercaptoethanol, and boiled at 90°C for 5 min. Proteins were separated by SDS-PAGE and transferred to PVDF membranes. Equal transfer was assessed by Ponceau S Staining reagent (Sigma Aldrich, St. Louis, MO.). Blots were then blocked 30 minutes at room temperature in PBS with 5% non-fat dry milk (NFDM). All primary antibodies were applied 1:1000 in PBS 1% tween, overnight at 4°C. Secondary antibodies were applied 1:2000 in PBS 5% NFDM for 1 hour at room temperature. Blots were probed for NF-κBp65 (Cell Signaling Technologies, Danvers, MA. 8242S). Histone H3 (Cell Signaling Technologies, Danvers, MA. 4499S) and β-tubulin (Cell Signaling Technologies, Danvers, MA. 15115S) were utilized for nuclear and cytoplasmic fractions, respectively. Blots were visualized with SuperSignal Chemiluminescent substrate containing horseradish peroxidase (ThermoFisher, Carlsbad, CA.) utilizing the ChemiDocXRS imaging system (BioRad, Irvine, CA.).

Antioxidant capacity assays

Cells were cultured and treated as Control or with TNF-α (10 ng/ml) alone or in combination with MSM (10 mg/ml) for 24 hours. Total antioxidant capacity was assessed via the Oxiselect Total Antioxidant Capacity assay kit, (Cell Biolabs, San Diego, CA.). Assessment of glutathione was performed with the Oxiselect Total Glutathione assay kit, (Cell Biolabs, San Diego, CA.). Cells were harvested for each assay according to provided protocol instructions. To measure Oxidized (GSSG) versus reduced (GSH) glutathione, GSH was derivatized with 2-vinylpyridine, allowing for measurement of GSSG only. GSH was calculated as the difference between measured GSSG and total glutathione levels [17].

Statistical analysis

All statistical analysis were performed on Sigma Plot Software (San Jose, CA.). Results are presented as means ± SEM with P < 0.05 accepted as statistically significant. Equal variance was tested and normality was confirmed with the Shapiro-Wilk test. Between groups differences were evaluated with t-tests or one-way analysis of variance (ANOVA) with Bonferroni post hoc when appropriate. The Mann-Whitney rank sum test or Kruskal-Wallis ANOVA on ranks was utilized in the case of unequal variance.
Methylsulfonylmethane decreases inflammatory response to TNF-α in cardiac cells

**Results**

*Cell viability and proliferation is not affected by MSM at doses of 20 mg/ml or less*

Initial experiments were undertaken to determine an appropriate dosage of MSM in the Ac16 cell model. Compared to cells cultured in the absence of MSM, no differences in cell viability or proliferation were detected at doses of 5, 10, or 20 mg/ml (Figure 1, Supplementary Data). However, significant reductions in cell viability occurred at a dosage of 40 mg/ml. While a reduction in cell viability at any concentration was unexpected, it should be noted that previous studies performed in different cell types have utilized doses well below 40 mg/ml. We have confirmed that MSM does not alter cell viability at a dosage of 20 mg/ml or below in Ac16 cells. Previous studies support the rationale that doses of MSM within this range exert positive physiological effects [14, 15].

*MSM decreases TNF-α mediated IL-6 release in Ac16 cells*

IL-6 was significantly elevated in the culture medium of cells treated with TNF-α compared to untreated control cells. Compared to cells treated with TNF-α alone, IL-6 levels were significantly decreased in culture medium from cells treated TNF-α combined with both 5.0 and 10 mg/ml MSM. However, cells treated with TNF-α in the presence of 2.5 mg/ml MSM were not different from cells treated with TNF-α alone (Figure 2, Supplementary Data). These results indicate that MSM effectively decreases activation of inflammatory pathways that occur in response to TNF-α at concentrations of 5-10 mg/ml. Based on these findings, further treatments were performed with 10 mg/ml MSM.

*MMS decreases TNF-α induced IL-6 mRNA transcript expression*

MSM alone resulted in lower expression of NFκβ1 and IL-1 compared to control cells. No other transcript levels were different between MSM and control cells (Figure 3, Supplementary Data). Treatment with TNFα resulted in elevated transcript expression of IL-6, IL-1, NFκβ1 & 2, and Iκβ compared to controls. Co-treatment of cells with TNFα and MSM significantly decreased IL-6 transcript expression compared to cells treated with TNFα alone. However, co-treatment with MSM did not significantly impact transcript expression of IL-1, NFκβ1 and 2, or Iκβ (Figure 4, Supplementary Data). It is important to note that this data reflects only a single time point, where differences may exist at different time points following treatment. Overall, the results support the notion that MSM reduces inflammatory signaling under basal conditions and in response to pathological stimuli.

*NFκB activation*

TNF-α treatment increased NFκB within the nuclear fraction, indicating that NFκB activation is increased by TNF-α. Co-treatment of TNF-α with MSM did not significantly decrease the amount of NFκB present in the nuclear fraction compared to TNF-α alone. Also, MSM treatment alone had no effect on NFκB compartmentalization compared to control treated cells.

*Antioxidant capacity assays*

Treatment of cells with MSM did not significantly impact the GSSG/GSH ratio, or the total anti-
Methylsulfonylmethane decreases inflammatory response to TNF-α in cardiac cells

oxidant capacity. Furthermore, no differences were found for these variables following treatment with TNF-α alone, or in combination with MSM.

Discussion

The key findings of this study indicate that MSM decreases both protein and transcript expression of IL-6 in response to pathological stimuli. Given the involvement of IL-6 in cardiac inflammation and cardiovascular disease, this finding supports the hypothesis that MSM may provide protection against inflammatory-mediated cardiovascular pathologies. Continued investigation of the potential benefits of MSM on the development and progression of cardiovascular diseases is highly warranted.

This was the first investigation to examine the effects of MSM in cardiac cells, specifically the AC16 cell model. In order to identify a proper treatment concentration of MSM, we first performed cell viability assays with varying concentrations of MSM. The concentrations were based upon work in different cell models [14, 15]. Our results indicated that MSM may decrease cell viability at very high concentrations, but had no effect on cell viability at most concentrations tested. The concentrations in which cell viability was unaffected are well within the concentrations found most frequently reported in studies utilizing different cell models [14, 15]. Next, the effect of various concentrations of MSM on IL-6 production following TNF-α treatment were examined to further identify an appropriate dose of MSM for the
Methylsulfonylmethane decreases inflammatory response to TNF-α in cardiac cells

The remainder of the study. The findings from these two experiments indicated that 5-10 mg/ml MSM is effective at diminishing TNF-α induced IL-6 production, while remaining well below the threshold that could impact cell viability. Therefore, a concentration of 10 mg/ml MSM was utilized for the remainder of the experiments.

The next objective of the study was to determine whether MSM had an effect on transcript expression of inflammatory markers, either alone or in combination with TNF-α treatment. MSM treatment resulted in decreased transcript expression of NF-κB1 and IL-1. These results indicate that MSM may have a role in decreasing inflammatory markers during basal conditions. TNF-α increased transcript expression of inflammatory pathway components (NF-κB1, NF-κB2, IkB, IL-1 and IL-6). Relative to cells treated with TNF-α, co-treatment with TNF-α and MSM decreased the transcript expression of IL-6, while the expression of NF-κB1, NF-κB2, IkB, and IL-1 was unaffected. Interestingly, while MSM decreased transcript expression of NF-κB1 and IL-1 under basal conditions, there was no effect when combined with TNF-α. Therefore, it appears the effect of TNF-α overrides the effect of MSM to decrease transcription of NF-κB and IL-1. It is important to note that these studies were performed at only one time point. It may be that transcriptional changes occur at times other than that which was observed in this study, and therefore MSM may have effects that were not observed.

We hypothesized that MSM diminishes IL-6 transcript and protein expression following TNF-α treatment by decreasing the level of NF-κB activation that occurs in response to TNF-α. NF-κB is a well-studied super family of transcription factors involved in transcriptional regulation of various inflammatory cytokines, such as TNF-α, IL-6, and IL-1 [18], as well as genes regulating oxidative status [19, 20]. Under basal conditions, inactive NF-κB is bound to inhibitor of κB (IkB) within the cytoplasm [21]. Activation of NF-κB occurs due to phosphorylation and degradation of IkB by IkB kinase (IKK), followed by translocation of NF-κB to the nucleus [21]. Therefore, the level of NF-κB activation was measured by examining the cellular location of NF-κB. TNF-α treatment resulted in significantly elevated NF-κB within the nuclear compartment compared to control treated cells. Although group means are decreased with TNF-α and MSM co-treatment compared to TNF-α alone, we did not find significant differences in NF-κB within the nuclear fraction. Samples were measured at 30 min post treatment application. This timeframe is based upon previous findings that indicate NF-κB is maximally activated at 30 min, and follows an oscillating pattern of activation [22]. Despite this, it is possible that the timing of sample collection may have been slightly different from when the peak activation occurred. Therefore, although the data does not support an effect of MSM on decreased NF-κB activation, further study is needed to confirm this finding and sample various timeframes following treatment. Additionally, future investigations should aim to determine the mechanisms by which MSM decreases expression of inflammatory markers.

The results of our antioxidant capacity assay did not reveal any effect associated with MSM treatment. Likewise, MSM treatment had no effect on the GSSG/GSH ratio, which is commonly used as a marker of oxidative stress. These findings were somewhat unexpected, as many have documented improved antioxidant capacity and decreased oxidative stress following MSM treatment. However, differences in our study and others could be due to both the difference in study model and timing. We have utilized an immortalized model of human heart cells, compared to other cell types or consumption in humans, as well as difference in treatment times, we examined 24 hours, while other studies have examined more prolonged supplementation in humans [12, 15]. Additional studies are needed to further clarify effects of MSM on oxidative status and antioxidant capacity in heart tissues.

In conclusion, the findings from this investigation indicate that MSM is effective in decreasing IL-6 transcript and protein expression following TNF-α treatment. This is the first investigation to examine the effects of MSM in a cardiac model. Given the role of chronic inflammation in cardiovascular disease, these findings support the importance of future studies to robustly identify the beneficial effects of MSM as a novel option for prevention and treatment of cardiovascular disease.
Methylsulfonylmethane decreases inflammatory response to TNF-α in cardiac cells

Acknowledgements

This work was supported by the College of Nursing at Washington State University and Bergstrom Nutrition, Vancouver, WA.

Disclosure of conflict of interest

None.

Address correspondence to: Lindsey E Miller, Department of Nutrition and Exercise Physiology, Elson S. Floyd College of Medicine, Washington State University, USA. E-mail: Lindsey.e.miller@wsu.edu

References


Methylsulfonylmethane decreases inflammatory response to TNF-α in cardiac cells

[19] Hirotani S, Otsu K, Nishida K, Higuchi Y, Morita T, Nakayama H, Yamaguchi O, Mano T, Matsu-


